BioLineRx (BLRX) News Today

BioLineRx Ltd. (NASDAQ:BLRX - Get Free Report) saw a large decrease in short interest in the month of July. As of July 15th, there was short interest totalling 119,700 shares, a decrease of 63.1% from the June 30th total of 324,300 shares. Based on an average daily volume of 347,600 shares, the days-to-cover ratio is currently 0.3 days.

BioLineRx Ltd. (NASDAQ:BLRX - Get Free Report) was the recipient of a large increase in short interest in June. As of June 30th, there was short interest totalling 324,300 shares, an increase of 52.9% from the June 15th total of 212,100 shares. Based on an average daily volume of 374,900 shares, the short-interest ratio is presently 0.9 days.

BioLineRx Ltd. (NASDAQ:BLRX - Get Free Report) was the recipient of a significant increase in short interest in May. As of May 31st, there was short interest totalling 356,200 shares, an increase of 62.6% from the May 15th total of 219,100 shares. Based on an average daily trading volume, of 427,300 shares, the short-interest ratio is currently 0.8 days.

BioLineRx Ltd. (NASDAQ:BLRX - Get Free Report) was the recipient of a large drop in short interest during the month of May. As of May 15th, there was short interest totalling 219,100 shares, a drop of 46.6% from the April 30th total of 410,600 shares. Based on an average daily volume of 410,600 shares, the days-to-cover ratio is currently 0.5 days.

BioLineRx (NASDAQ:BLRX - Get Free Report) released its quarterly earnings results on Tuesday. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.28. The firm had revenue of $6.86 million for the quarter, compared to analyst estimates of $0.34 million. During the same period in the prior year, the business earned ($0.15) earnings per share.

HC Wainwright reiterated a "buy" rating and issued a $21.00 price objective on shares of BioLineRx in a research note on Wednesday.

BioLineRx Ltd. (NASDAQ:BLRX - Get Free Report) was the target of a significant decline in short interest in April. As of April 30th, there was short interest totalling 410,600 shares, a decline of 47.6% from the April 15th total of 783,600 shares. Based on an average daily volume of 416,500 shares, the days-to-cover ratio is currently 1.0 days.

StockNews.com upgraded shares of BioLineRx to a "sell" rating in a research report on Friday.

BioLineRx Ltd. (NASDAQ:BLRX - Free Report) - Investment analysts at HC Wainwright cut their FY2024 earnings estimates for BioLineRx in a report issued on Tuesday, March 26th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will post earnings of ($1.03) per share for

BioLineRx Ltd. (NASDAQ:BLRX - Get Free Report) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 324,700 shares, an increase of 76.6% from the February 29th total of 183,900 shares. Based on an average daily trading volume, of 316,300 shares, the days-to-cover ratio is presently 1.0 days.

BioLineRx Ltd. (NASDAQ:BLRX - Free Report) - Analysts at HC Wainwright issued their Q1 2024 earnings estimates for shares of BioLineRx in a research note issued to investors on Tuesday, March 26th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will earn ($0.29) per s

StockNews.com upgraded shares of BioLineRx to a "sell" rating in a report on Wednesday.

BioLineRx (NASDAQ:BLRX - Get Free Report) issued its quarterly earnings results on Tuesday. The biotechnology company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.07. The business had revenue of $4.80 million for the quarter, compared to analyst estimates of $0.17 million. During the same quarter in the prior year, the firm earned ($0.09) EPS.

HC Wainwright reiterated a "buy" rating and issued a $21.00 price target on shares of BioLineRx in a research note on Tuesday.

BioLineRx (NASDAQ:BLRX) will be releasing earnings before the market opens on Tuesday, March 26, Zacks reports.

BioLineRx Ltd. (NASDAQ:BLRX - Get Free Report) was the target of a large decline in short interest during the month of February. As of February 29th, there was short interest totalling 183,900 shares, a decline of 8.1% from the February 14th total of 200,000 shares. Based on an average trading volume of 313,400 shares, the days-to-cover ratio is currently 0.6 days.

BioLineRx Ltd. (NASDAQ:BLRX - Get Free Report) saw a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 114,800 shares, a decrease of 59.2% from the November 30th total of 281,100 shares. Based on an average daily trading volume, of 430,400 shares, the days-to-cover ratio is presently 0.3 days.